Palvella Therapeutics PVLA Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Returns | ||||||
| Return on equity | -34.2%— | -92.1%— | —— | —— | —— | |
| Return on assets | -28.7%+13.7pp | -56.5%-20.0pp | -75.4%-138pp | -57.5%-95.1pp | -42.4%-94.9pp | |
| Liquidity | ||||||
| Current ratio | 28.9×+20.0× | 5.2×-2.1× | 6.5×— | 7.7×— | 8.8×— | |
| Quick ratio | 28.9×+20.0× | 5.2×-2.1× | 6.5×— | 7.7×— | 8.8×— | |
| Cash ratio | 22.6×+14.2× | 5.1×-1.8× | 6.2×+1.6× | 7.3×+4.2× | 8.4×+5.9× | |
| Leverage | ||||||
| Debt-to-equity | 0×— | 0×— | —— | —— | —— | |
| Debt-to-assets | 0×— | 0×— | —— | —— | —— | |
| Per Share | ||||||
| Book value per share | $17.75+252% | $2.49-91.2% | $3.50+107% | $4.32+109% | $5.05+112% | |
| Valuation | ||||||
| Market capitalization | $1.78B+468% | $1.24B+820% | $693.33M— | $243.89M— | $314.08M— | |
| Enterprise value | $1.58B— | $1.18B— | —— | —— | —— | |
| Price / book | 7.7×+2.0× | 44.3×+42.1× | 17.9×— | 5.1×— | 5.7×— | |
| Earnings yield | -2.8%+4.6pp | -3.4%+9.6pp | -4.8%— | -11.6%— | -7.3%— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Palvella Therapeutics's ratios come from?
- Every ratio is computed from Palvella Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.